Tirzepatide – 5mg

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist — a single molecule that activates two incretin pathways at once. In peptide research this dual mechanism has drawn intense interest for its effects on appetite signaling, insulin response and body-weight regulation.

In the landmark 72-week SURMOUNT-1 trial, participants on the 15 mg dose recorded a mean body-weight reduction of 20.9%, versus 3.1% on placebo^[1]. 57% of that group lost a fifth or more of their body weight, and 91% lost at least 5%^[1].

Head-to-head data reinforce the signal: in SURPASS-2, tirzepatide produced greater weight loss than semaglutide — up to 5.5 kg more at the top dose — while lowering HbA1c by 2.30 points^[2]. Its dual-receptor design is widely cited as why it outperforms single-pathway GLP-1 agonists^[3].

Supplied as a lyophilized powder for reconstitution. Figures above summarize published clinical findings on the tirzepatide molecule and are provided as scientific reference for laboratory research only.